Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01425216 · ClinicalTrials.gov registry record · Phase 2
Sorafenib for Patients With Extensive Keloids
A Phase 2 study, sponsored by Tirgan, Michael H., M.D..
- Terminated
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT01425216 is a Phase 2 study that was terminated before completion, run by Tirgan, Michael H., M.D.. The registered enrollment target is 60 participants.
The verdict
NCT01425216, a Phase 2 study, was terminated before completion, sponsored by Tirgan, Michael H., M.D..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
Treatment of keloid disorder is an area of unmet medical need. Current treatments for keloid partially address small and localized keloids, yet there are no wholly satisfactory or effective treatments for patients with extensive keloids. Such patients may benefit from effective systemic treatments. Sorafenib has the potential to regulate the three known dysregulated biological pathways in keloid tissue.
Interventions
- DRUG Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2013-03 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01425216
The ClinicalTrials.gov registry entry for NCT01425216 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tirgan, Michael H., M.D., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sorafenib is the first listed.
NCT01425216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01425216 about?
NCT01425216 is a clinical study titled "Sorafenib for Patients With Extensive Keloids". Treatment of keloid disorder is an area of unmet medical need. Current treatments for keloid partially address small and localized keloids, yet there are no wholly satisfactory or effective treatments for patients with extensive keloids. Such patients may benefit from effective systemic treatments. ...
What is the current status of trial NCT01425216?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2013-03. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01425216?
The interventions under investigation include: Sorafenib (DRUG).
Who is sponsoring clinical trial NCT01425216?
This trial is sponsored by Tirgan, Michael H., M.D., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.